A Good Week for OSSIO

Last week was a great week for OSSIO with the FDA approval of its pediatric indications and presentation at the International Pediatric Orthopedic Society (IPOS) meeting in Orlando, FL. 

FDA approval

The FDA has cleared the company’s OSSIOfiber® bio-integrative fixation technology for use in orthopedic surgery for children and adolescents needing bone fractures fixed, osteotomies, or fusions. As a result, OSSIOfiber Compression Screws and Trimmable Fixation Nails are now available for use in children ages two to 21 years in standard clinical practice. 

Presentation at IPOS

Click here for the infographic, presented at IPOS 2023, that shows the study’s results indicating that “bio-integrative fixation devices provide radiographic fracture healing rates comparable to metal-alloy devices in treating transitional ankle fractures, while offering advantages in terms of complication rates, re-operation rates, cost-efficiency for patients, and quality of life.”